Epigenetic mechanisms in the biology of prostate cancer

Seminars in Cancer Biology

Volumn 19, Issue 3, 2009, Pages 172-180

  Schulz, Wolfgang A ^a   Hoffmann, Michèle J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Androgen; Cancer stem cells; Chromatin; DNA methylation; Polycombs

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; POLYCOMB GROUP PROTEIN;

CANCER CELL; CANCER GROWTH; CHROMATIN; DNA METHYLATION; EPIGENETICS; GENE CONTROL; HUMAN; INNATE IMMUNITY; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW;

ANDROGENS; ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 63449105238     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.02.006     Document Type: Review

References (101)

1. Ribeiro F.R., Henrique R., Hektoen M., Berg M., Jeronimo C., Teixeira M.R., et al. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer 5 (2006) 33
2. Sun J., Liu W., Adams T.S., Sun J., Li X., Turner A.R., et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67 (2007) 692-700
3. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
4. Lapointe J., Li C., Giacomini C.P., Salari K., Huang S., Wang P., et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 67 (2007) 8504-8510
5. Mehra R., Tomlins S.A., Yu J., Cao X., Wang L., Menon A., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68 (2008) 3584-3590
6. Nam R.K., Sugar L., Yang W., Srivastava S., Klotz L.H., Yang L.Y., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97 (2007) 1690-1695
7. Abate-Shen C., and Shen M.M. Molecular genetics of prostate cancer. Genes Dev 14 (2000) 2410-2434
8. Li L.C., Okino S.T., and Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 1704 (2004) 87-102
9. Nelson W.G., Yegnasubramanian S., Agoston A.T., Bastian P.J., Lee B.H., Nakayama M., et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 12 (2007) 4254-4266
10. Florl A.R., Steinhoff C., Muller M., Seifert H.H., Hader C., Engers R., et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91 (2004) 985-994
11. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.C., et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11 (2005) 6582-6588
12. Zhu X., Leav I., Leung Y.K., Wu M., Liu Q., Gao Y., et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164 (2004) 2003-2012
13. Aitchison A., Warren A., Neal D., and Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67 (2007) 638-644
14. Guan M., Zhou X., Soulitzis N., Spandidos D.A., and Popescu N.C. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 12 (2006) 1412-1419
15. Hornstein M., Hoffmann M.J., Alexa A., Yamanaka M., Muller M., Jung V., et al. Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5 (2008) 123-136
16. Benbrahim-Tallaa L., Waterland R.A., Dill A.L., Webber M.M., and Waalkes M.P. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect 115 (2007) 1454-1459
17. Liu L., Zhang J., Bates S., Li J.J., Peehl D.M., Rhim J.S., et al. A methylation profile of in vitro immortalized human cell lines. Int J Oncol 26 (2005) 275-285
18. Morey Sr. K., Smiraglia D.J., James S.R., Moser M.T., Foster B.A., and Karpf A.R. Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 6 (2008) 1365-1374
19. Yegnasubramanian S., Haffner M.C., Zhang Y., Gurel B., Cornish T.C., Wu Z., et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68 (2008) 8954-8967
20. Hoffmann M.J., Muller M., Engers R., and Schulz W.A. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72 (2006) 1577-1588
21. Hoffmann M.J., Florl A.R., Seifert H.H., and Schulz W.A. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 114 (2005) 406-413
22. Lodygin D., Epanchintsev A., Menssen A., Diebold J., and Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65 (2005) 4218-4227
23. Fu V.X., Dobosy J.R., Desotelle J.A., Almassi N., Ewald J.A., Srinivasan R., et al. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 68 (2008) 6797-6802
24. Kawamoto K., Okino S.T., Place R.F., Urakami S., Hirata H., Kikuno N., et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13 (2007) 2541-2548
25. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
26. Xiang Y., Zhu Z., Han G., Lin H., Xu L., and Chen C.D. JMJD3 is a histone H3K27 demethylase. Cell Res 17 (2007) 850-857
27. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66 (2006) 10242-10246
28. Setlur S.R., Mertz K.D., Hoshida Y., Demichelis F., Lupien M., Perner S., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100 (2008) 815-825
29. Gunster M.J., Raaphorst F.M., Hamer K.M., den Blaauwen J.L., Fieret E., Meijer C.J., et al. Differential expression of human Polycomb group proteins in various tissues and cell types. J Cell Biochem Suppl Suppl. 36 (2001) 129-143
30. Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102 (2005) 1859-1864
31. Huffman D.M., Grizzle W.E., Bamman M.M., Kim J.S., Eltoum I.A., Elgavish A., et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67 (2007) 6612-6618
32. Hoffmann M.J., Engers R., Florl A.R., Otte A.P., Muller M., and Schulz W.A. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6 (2007) 1403-1412
33. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
34. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22 (2003) 5323-5335
35. Saramaki O.R., Tammela T.L., Martikainen P.M., Vessella R.L., and Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45 (2006) 639-645
36. Berezovska O.P., Glinskii A.B., Yang Z., Li X.M., Hoffman R.M., and Glinsky G.V. Essential role for activation of the polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5 (2006) 1886-1901
37. Sander S., Bullinger L., Klapproth K., Fiedler K., Kestler H.A., Barth T.F., et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112 (2008) 4202-4212
38. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008)
39. van Leenders G.J., Dukers D., Hessels D., van den Kieboom S.W., Hulsbergen C.A., Witjes J.A., et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52 (2007) 455-463
40. Valk-Lingbeek M.E., Bruggeman S.W., and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 118 (2004) 409-418
41. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20 (2006) 1123-1136
42. Ringrose L. Polycomb comes of age: genome-wide profiling of target sites. Curr Opin Cell Biol 19 (2007) 290-297
43. Pietersen A.M., and van Lohuizen M. Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 20 (2008) 201-207
44. Schwartz Y.B., and Pirrotta V. Polycomb complexes and epigenetic states. Curr Opin Cell Biol 20 (2008) 266-273
45. Mohn F., Weber M., Rebhan M., Roloff T.C., Richter J., Stadler M.B., et al. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30 (2008) 755-766
46. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
47. Rajasekhar V.K., and Begemann M. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25 (2007) 2498-2510
48. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 (2007) 232-236
49. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat Genet 39 (2007) 157-158
50. Chen H., Tu S.W., and Hsieh J.T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280 (2005) 22437-22444
51. Schulz W.A., and Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 10 (2006) 100-125
52. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39 (2007) 237-242
53. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40 (2008) 741-750
54. Gal-Yam E.N., Egger G., Iniguez L., Holster H., Einarsson S., Zhang X., et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci USA 105 (2008) 12979-12984
55. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7 (2006) 21-33
56. Bryant R.J., Cross N.A., Eaton C.L., Hamdy F.C., and Cunliffe V.T. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67 (2007) 547-556
57. Bryant R.J., Winder S.J., Cross S.S., Hamdy F.C., and Cunliffe V.T. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 68 (2008) 255-263
58. Hoffmann M.J., and Schulz W.A. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 83 (2005) 296-321
59. Wilson A.S., Power B.E., and Molloy P.L. DNA hypomethylation and human diseases. Biochim Biophys Acta 1775 (2007) 138-162
60. Santourlidis S., Florl A., Ackermann R., Wirtz H.C., and Schulz W.A. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39 (1999) 166-174
61. McCabe M.T., Davis J.N., and Day M.L. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. Cancer Res 65 (2005) 3624-3632
62. Pradhan S., and Kim G.D. The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity. EMBO J 21 (2002) 779-788
63. Schulz W.A., Elo J.P., Florl A.R., Pennanen S., Santourlidis S., Engers R., et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35 (2002) 58-65
64. Huang Y.C., Lee C.M., Chen M., Chung M.Y., Chang Y.H., Huang W.J., et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 13 (2007) 1412-1420
65. Rhodes D.R., Barrette T.R., Rubin M.A., Ghosh D., and Chinnaiyan A.M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62 (2002) 4427-4433
66. Kokkinakis D.M., Liu X., Chada S., Ahmed M.M., Shareef M.M., Singha U.K., et al. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 64 (2004) 7513-7525
67. Suzuki M., Shigematsu H., Shivapurkar N., Reddy J., Miyajima K., Takahashi T., et al. Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242 (2006) 222-230
68. Baader E., Toloczko A., Fuchs U., Schmid I., Beltinger C., Ehrhardt H., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 65 (2005) 7888-7895
69. Schulz W.A., Alexa A., Jung V., Hader C., Hoffmann M.J., Yamanaka M., et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6 (2007) 14
70. Xiang Y., Wang Z., Murakami J., Plummer S., Klein E.A., Carpten J.D., et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res 63 (2003) 6795-6801
71. Bettoun D.J., Scafonas A., Rutledge S.J., Hodor P., Chen O., Gambone C., et al. Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways. J Biol Chem 280 (2005) 38898-38901
72. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 7 (2007) 256-269
73. Dong B., Kim S., Hong S., Das G.J., Malathi K., Klein E.A., et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 104 (2007) 1655-1660
74. Fischer N., Hellwinkel O., Schulz C., Chun F.K., Huland H., Aepfelbacher M., et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 43 (2008) 277-283
75. Fridman A.L., and Tainsky M.A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27 (2008) 5975-5987
76. Finkel T., Serrano M., and Blasco M.A. The common biology of cancer and ageing. Nature 448 (2007) 767-774
77. Andersen J.B., Li X.L., Judge C.S., Zhou A., Jha B.K., Shelby S., et al. Role of 2-5A-dependent RNase-L in senescence and longevity. Oncogene 26 (2007) 3081-3088
78. Schulz W.A., Steinhoff C., and Florl A.R. Methylation of endogenous human retroelements in health and disease. Curr Top Microbiol Immunol 310 (2006) 211-250
79. Goodier J.L., and Kazazian Jr. H.H. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 135 (2008) 23-35
80. Rodriguez J., Vives L., Jorda M., Morales C., Munoz M., Vendrell E., et al. Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res 36 (2008) 770-784
81. Wang-Johanning F., Frost A.R., Jian B., Azerou R., Lu D.W., Chen D.T., et al. Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. Cancer 98 (2003) 187-197
82. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
83. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58 (1998) 5310-5314
84. Heemers H.V., and Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28 (2007) 778-808
85. Lan F., Nottke A.C., and Shi Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 20 (2008) 316-325
86. Wissmann M., Yin N., Muller J.M., Greschik H., Fodor B.D., Jenuwein T., et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9 (2007) 347-353
87. Xiang Y., Zhu Z., Han G., Ye X., Xu B., Peng Z., et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 104 (2007) 19226-19231
88. Yamane K., Toumazou C., Tsukada Y., Erdjument-Bromage H., Tempst P., Wong J., et al. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125 (2006) 483-495
89. Urbanucci A., Waltering K.K., Suikki H.E., Helenius M.A., and Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer 8 (2008) 219
90. Wang J., Scully K., Zhu X., Cai L., Zhang J., Prefontaine G.G., et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446 (2007) 882-887
91. Metzger E., Wissmann M., Yin N., Muller J.M., Schneider R., Peters A.H., et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437 (2005) 436-439
92. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., et al. p53 is regulated by the lysine demethylase LSD1. Nature 449 (2007) 105-108
93. Guil S., and Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 41 (2009) 87-95
94. Marson A., Levine S.S., Cole M.F., Frampton G.M., Brambrink T., Johnstone S., et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134 (2008) 521-533
95. Ozen M., Creighton C.J., Ozdemir M., and Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27 (2008) 1788-1793
96. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., and Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 67 (2007) 6130-6135
97. Ambs S., Prueitt R.L., Yi M., Hudson R.S., Howe T.M., Petrocca F., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68 (2008) 6162-6170
98. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14 (2008) 1271-1277
99. Glinsky G.V. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26 (2008) 2846-2853
100. Koeneman K.S., Yeung F., and Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39 (1999) 246-261
101. Vander Griend D.J., Karthaus W.L., Dalrymple S., Meeker A., DeMarzo A.M., and Isaacs J.T. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68 (2008) 9703-9711